Filing Flows

Filing Flows › Harmony Biosciences Holdings (HRMY) › Q2 2025

Harmony Biosciences Holdings (HRMY) Q2 2025 earnings results (second quarter 2025)

10-Q filed Aug 5, 2025

Harmony Biosciences Holdings (HRMY) reported revenue of $200M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +9% from the quarter before. Operating margin was 24.0%, net earnings $39.8M (19.8% of revenue).

Revenue$200M
Year over year+16%
Quarter over quarter+9%
Operating margin24.0%
Net earnings$39.8M

Harmony Biosciences Holdings, Q2 2025: revenue $200M (+16% year over year), operating margin 24.0%, net earnings $39.8M, operating cash flow $79.3M. The chart follows the revenue to costs, profit and cash.

Q2 2025AmountQ/QY/Y
Revenue$200M+9%+16%
Gross profit$162M+6%+15%
Operating profit$48.2M-14%+126%
Net earnings$39.8M-13%+243%
Operating cash flow$79.3M+133%+86%
Free cash flow$79.3M+134%+89%

What changed

Revenue was $200.5M in Q2 2025, up 16% year over year and up 9% from the previous quarter.

Gross margin was 81.0%, down 0.4 points from a year earlier. Operating profit was $48.2M, a 24.0% margin (up 11.7 points year over year). Of the extra revenue versus a year earlier, 97% reached operating profit, above the 12% margin then. Operating expenses fell 4% while revenue rose 16%. The fastest-growing cost line was General & admin (+25%). Net earnings were $39.8M, up 243% year over year. The effective tax rate was 19.9%.

Operating cash flow was $79.3M (up 86% year over year), 199% of net earnings. Non-cash charges added back $6.0M of depreciation and amortization and $11.5M of share-based compensation. Working capital and other items added $22.1M. Capital expenditures of $4K left free cash flow of $79.3M.

Questions

What was Harmony Biosciences Holdings' revenue in the second quarter 2025?

Harmony Biosciences Holdings (HRMY) reported revenue of $200M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +9% from the quarter before.

Was Harmony Biosciences Holdings profitable in the second quarter 2025?

Operating profit was $48.2M (24.0% of revenue) and net earnings $39.8M.

Open the interactive Sankey →

Source: Harmony Biosciences Holdings 10-Q on SEC EDGAR.